TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19067285
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 5 to 10 ppm
Study: 9476183
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg/lansoprazole 15 mg
Study: 9476183
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg/placebo
Study: 9476183
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg/ranitidine 150 mg
Study: 9476183
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg/placebo
Study: 9476183
Drug: lansoprazole (half
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (half dose formulation)
Study: 3680603
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 1 mg alprazolam
Study: 3680603
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1 mg alprazolam
Study: 26771737
Drug: Citalopram (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (30 mg/day, titrated over 3 weeks)
Study: 24410954
Drug: n-3 FA
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA supplement (2.3 g daily for 6 months)
Study: 16086704
Drug: 7-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Study: 16086704
Drug: 10-day rabeprazole-based
Normalized name: rabeprazole sodium 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Study: 15786549
Drug: 7-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day rabeprazole-based triple therapy
Study: 16086704
Drug: 10-day rabeprazole-based
Normalized name: rabeprazole sodium 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day rabeprazole-based triple therapy
Study: 6116728
Drug: Hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + cimetidine (300 mg q.i.d.)
Study: 6116728
Drug: Hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + placebo
Study: 6116728
Drug: Hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + terbutaline (2.5 mg q.i.d.)
Study: 6116728
Drug: Hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + cyproheptadine (4 mg q.i.d.)
Study: 6116728
Drug: Hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + chlorpheniramine (4 mg q.i.d.)
Study: 24941138
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh extract 40 mg/day
Study: 23328330
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 to 50 mg/d)
Study: 23328330
Drug: Divalproate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproate (500 to 750 mg/d)
Study: 21461792
Drug: Dexmedetomidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (2 μg·kg(‐1) and 4 μg·kg(‐1) combined)
Study: 21461792
Drug: Dexmedetomidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (2 μg·kg(‐1))
Study: 21461792
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 μg·kg(‐1))
Study: 19125241
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg idebenone
Study: 19125241
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg idebenone
Study: 19125241
Drug: idebenone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: idebenone (up to 2,250 mg/day)
Study: 11707794
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 0.25%, 12 mL
Study: 30544518
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (0 to 7 mg/kg/day for six months)
Study: 24397061
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid injection (triamcinolone 20 mg mixed with lignocaine 2% 1 cc) and topical NSAID cream (diclofenac diethylammonium) twice a day, tab. diclofenac sodium 50 mg twice a day for 3 weeks
Study: 24397061
Drug: Tab diclofenac
Normalized name: diclofenac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab diclofenac 50 mg twice a day and topical NSAID cream application twice a day for 3 weeks
Study: 18706164
Drug: OROS‐MPH (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS‐MPH (18 mg/time, once daily)
Study: 18706164
Drug: IR‐MPH (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR‐MPH (5 mg/time, twice or three times per day)
Study: 15482357
Drug: Effervescent ASA
Normalized name: aspirin Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent ASA (1000 mg)
Study: 16109110
Drug: Sumatriptan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (50 mg)
Study: 11182878
Drug: PAS intervention
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS intervention (structured counselling programme, information leaflet, follow-up weekly for the first 4 weeks then monthly as needed)
Study: 9608351
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 25 mg per day
Study: 9608351
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 50 mg per day
Study: 9608351
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 75 mg per day
Study: 7995316
Drug: Scopolamine-TTS (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine-TTS (1.5 mg)
Study: 21113636
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injection with 20 ml volume (5 ml contrast, 2 ml Triamcinolone, 13 ml local anaesthetic)
Study: 18290733
Drug: Ropivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (5 injections of 2 mL 0.5% ropivacaine around the ureteral orifice)
Study: 18290733
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 injections of 2 mL of 0.9% normal saline)
Study: 12589284
Drug: Injection molded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection molded and microwave polymerized (Microbase)
Study: 12589284
Drug: Injection molded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection molded and microwave polymerized (Acron MC)
Study: 12589284
Drug: Injection molded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection molded and conventionally polymerized (Success)
Study: 11238495
Drug: MK-677 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 (25 mg)
Study: 8449202
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (70 mmol)
Study: 24275677
Drug: Alendronate 70mg
Normalized name: ALENDRONATE 70MG TAB
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 70mg weekly
Study: 22143734
Drug: 2% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% NaF solution
Study: 22143734
Drug: GLUMA® (HEMA-G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLUMA® (HEMA-G)
Study: 7871004
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 mg orally)
Study: 3096345
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotic prophylaxis) for wounds >1 cm requiring suturing
Study: 24162387
Drug: 5-fluorouracil continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil continuous infusion (5-FUci)
Study: 24162387
Drug: Second-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line chemotherapy with new drugs
Study: 10436948
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (CAT) 250‐500 mg, twice daily orally for 7‐10 days
Study: 10436948
Drug: Cefixime (CFX)
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime (CFX) 200 mg, twice daily orally for 7‐10 days
Study: 8248693
Drug: Intracervical Foley
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Foley catheter with balloon inflated to 50 cc
Study: 8248693
Drug: Extraamniotic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraamniotic injection of prostaglandins E2 via a Foley catheter with balloon inflated to 50 cc
Study: 3516907
Drug: 3% benzydamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% benzydamine cream
Study: 31282567
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg once daily during ICU stay
Study: 31282567
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) once daily during ICU stay
Study: 23930551
Drug: GAKIC (10.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAKIC (10.2 g)
Study: 16489434
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg baclofen (BAC)
Study: 14689713
Drug: TN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TN therapy
Study: 8824690
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 46 mg kg-1 infused in 30 min
Study: 8824690
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 46 mg kg-1 infused in 30 min (2 doses)
Study: 1314144
Drug: ICI 169,369
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 169,369 (30 mg x 2)
Study: 1314144
Drug: ICI 169,369
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 169,369 (80 mg x 2)
Study: 30777118
Drug: 100,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 IU vitamin D3 (two oral doses, once in the fall and once in the winter)
Study: 27389681
Drug: PA21 (sucroferric
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA21 (sucroferric oxyhydroxide) 250 mg, 500 mg, 750 mg, or 1000 mg three times/day for 6 weeks
Study: 24742292
Drug: 5HT antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5HT antagonist
Study: 19707983
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg/d for 6 days
Study: 18027401
Drug: 0.4% stannous
Normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% stannous fluoride gel (control group)
Study: 20627920
Drug: Albuterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (180 microg)
Study: 10540090
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg x kg‐1
Study: 2663585
Drug: Ibopamine 100
Normalized name: ibopamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 100 mg t.i.d.
Study: 394144
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg per day for three days)
Study: 31200893
Drug: Intramuscular trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular trivalent inactivated influenza vaccine (IIV3)
Study: 24784420
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy (ART) recommendations without GC test result knowledge
Study: 24784420
Drug: Treatment intensity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensity
Study: 23567146
Drug: Trastuzumab, lapatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab, lapatinib, or their combination with paclitaxel before surgery
Study: 20047724
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral therapy (CBT) for OCD
Study: 20047724
Drug: Integrated cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive-behavioral therapy (CBT) focusing on MDD in the first phase and OCD in the second phase
Study: 17089228
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dexketoprofen
Study: 15612853
Drug: Addiction treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addiction treatments (specifics not provided)
Study: 12861852
Drug: Acetaminophen (paracetamol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (paracetamol)
Study: 11567541
Drug: Coxibs (COX-2-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coxibs (COX-2-specific inhibitors)
Study: 9258859
Drug: GHB 30
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 30 mg/kg
Study: 8355645
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early treatment group (ET Gr)
Study: 8355645
Drug: Postdischarge treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postdischarge treatment group (PDT Gr)
Study: 3300841
Drug: Potassium supplements
Normalized name: POTASSIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplements (48 mmol daily)
Study: 3300841
Drug: Potassium supplements
Normalized name: POTASSIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplements (24 mmol daily) in a subgroup of 13 patients
Study: 30089798
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 300 mg twice daily for 8 weeks
Study: 30089798
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 IU twice daily for 8 weeks
Study: 17851535
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine 0 mg/70 kg
Study: 17851535
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine 12 mg/70 kg
Study: 17851535
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine 25 mg/70 kg
Study: 17851535
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine 50 mg/70 kg
Study: 15866571
Drug: P and
Normalized name: P and S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P and 2 mg of E2
Study: 15866571
Drug: P and
Normalized name: P and S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P and 6 mg of E2
Study: 12419088
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (Climara, 50 microg 17beta‐estradiol for 3 months)
Study: 7862384
Drug: 100-g GTT
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g GTT
Study: 7862384
Drug: 50-g GTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-g GTT
Study: 7862384
Drug: 75-g GTT
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-g GTT
Study: 1936482
Drug: Bed-time NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bed-time NPH insulin (0.2 U/Kg)
Study: 1936482
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg x 3)
Study: 25265004
Drug: Early aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early aqueous suppression therapy (β‐blockers, α‐agonists, or carbonic anhydrase inhibitors) initiated when postoperative IOP >10 mm Hg (low‐IOP initiation group)
Study: 25265004
Drug: Early aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early aqueous suppression therapy (β‐blockers, α‐agonists, or carbonic anhydrase inhibitors) initiated when postoperative IOP >17 mm Hg (moderate‐IOP initiation group)
Study: 25265004
Drug: Early aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early aqueous suppression therapy (initiated before HP onset)
Study: 25265004
Drug: Therapy initiated
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy initiated after HP onset
Study: 18773327
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 200 mcg
Study: 18773327
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone 125 mcg
Study: 18773327
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide and fluticasone (both used on different occasions)
Study: 18773327
Drug: 4-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-day treatment protocol
Study: 18773327
Drug: 8-day treatment
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-day treatment protocol
Study: 18773327
Drug: 8-day treatment
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-day treatment protocol + azithromycin
Study: 15742421
Drug: Killing Hp
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killing Hp quadruple therapy (group B: lansoprazole 30 mg qd, clarithromycin 250 mg bid, amoxycillin 500 mg tid for 10 d, plus killing H pylori capsule 6 capsules bid for 4 wk)
Study: 15742421
Drug: New triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: New triple therapy (group A: lansoprazole 30 mg qd, clarithromycin 250 mg bid, amoxycillin 500 mg tid for 10 d)
Study: 15742421
Drug: Placebo (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (group C: gastropine 3 tablets bid for 4 wk)
Study: 15742421
Drug: Killing Hp
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killing Hp quadruple therapy (group B)
Study: 15742421
Drug: New triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: New triple therapy (group A)
Study: 12023699
Drug: Nebulized magnesium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulfate (384 mg in 6 mL of sterile water) plus albuterol (2.5 mg/3 mL)
Study: 12023699
Drug: Albuterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2.5 mg/3 mL) alone
Study: 10754431
Drug: isopolicosanol (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: isopolicosanol (3.6 mg/die for 7 days)
Study: 10754431
Drug: octacosanol (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: octacosanol (3.6 mg/die for 7 days)
Study: 8867776
Drug: Salt depletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt depletion (SD) with low sodium chloride dietary intake (< or = 60 mmol per day) and combined treatment with natriuretic and potassium sparing drugs
Study: 8867776
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment in the SD group
Study: 8867776
Drug: LVP low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LVP low-dose infusion during hypotonic polyuria
Study: 6743784
Drug: Cimetidine formulation
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine formulation A
Study: 6743784
Drug: Cimetidine formulation
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine formulation B
Study: 30520208
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment combined with lifestyle intervention (Weight Watchers)
Study: 26865390
Drug: BTH1677 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTH1677 at 0.5, 1, 2, 4, or 6 mg/kg (Phase 1a)
Study: 26865390
Drug: BTH1677 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTH1677 at 1, 2, or 4 mg/kg (Phase 1b)
Study: 24618964
Drug: Perioperative behavioral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative behavioral therapy with pelvic floor muscle training (BPMT)
Study: 8548891
Drug: Ticlopidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine and aspirin therapy
Study: 1824790
Drug: Zoladex (goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (goserelin acetate implant)
Study: 1824790
Drug: Serum testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum testosterone levels < 6.9 nmol/L
Study: 30373539
Drug: Tighter glycaemic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tighter glycaemic targets (fasting plasma glucose ≤5.0 mmol/L, 1 h postprandial ≤7.4 mmol/L, 2 h postprandial ≤6.7 mmol/L)
Study: 30373539
Drug: Less tight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less tight glycaemic targets (fasting plasma glucose < 5.5 mmol/L; 1 h postprandial < 8.0 mmol/L; 2 h postprandial < 7.0 mmol/L)
Study: 26438533
Drug: S-flurbiprofen plaster
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-flurbiprofen plaster (SFPP) 20 mg applied for 12 hours
Study: 26438533
Drug: S-flurbiprofen plaster
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-flurbiprofen plaster (SFPP) 2-60 mg applied for 24 hours